BioLargo earnings date
Want to see BLGO full AI Analyst Report?
BioLargo (BLGO) Q2 2026 Earnings Report
BLGO Q2 2026 EPS Results
- Actual EPS
- -$0.01
- Consensus EPS
- -$0.01
- Beat/Miss
- Met expectations
- One Year Ago EPS
- $0.00
BLGO Q2 2026 Revenue Results
- Actual Revenue
- $1.25M
- Expected Revenue
- $1.29M
- Beat/Miss
- Missed by -$47.00K
- YoY Revenue Growth
- -55.06%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/17/2026
- Time
- Before Open
- Conference Call
- Monday, August 17, 2026
BioLargo's next earnings date is estimated for November 18, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call was strongly forward-looking and optimistic, emphasizing revenue growth in the core engineering business, multiple distribution channels for Clyra, PFAS commercial progress, new ventures, and potential contract opportunities. However, management also acknowledged a difficult year marked by a market capitalization decline of more than 60%, the loss of the Pooph business, a close to $4 million write-down, Clyra’s launch delay and burn rate, and ongoing financing and regulatory uncertainty. The number and strength of the stated achievements and initiatives outweighed the stated challenges.
Management expects to launch the consumer products category in the October time frame, with a conservative target of about half the numbers that Pooph generated, realistically coming in the $15-plus million range over the first course of a year to 1.5 years; Clyra’s national distribution launch is targeted for 2027 start, with a 3- to 6-month setup, while its 3 active distributors encompass probably 70-plus percent of the market. Cellinity’s strategy involves factories with about $250 million of CapEx, factories of about $170 million each, incentives as much as 50% of CapEx, and a Puerto Rico project where 80-plus percent of the project can get financed with incentives; its design targets 10 years, no degradation and another 10-year cycle with only 4% degradation, versus a 7-year market with up to 15% degradation. The minerals facility is expected to move to Phase 2, probably somewhere around the $10 million range, take about a year, 1.5 years, and potentially lead to a design build probably something in the $40 million range; water projects being scoped include $5 million, $10 million, $25 million and $30 million projects, including systems of 3 million gallons a day, with a proposed 80% reduction in OpEx. A multimillion-dollar military grant is hoped to get funded in Q1, and the annual meeting target is December 1.
- Core Engineering Business Revenue GrowthQuarter-to-quarter revenue increased, with growth driven by the engineering group’s increased sales to third-party customers. The remainder of the products and services provided by ONM also increased, and management described the core business as growing and stable.
- Lean Parent Company OverheadManagement stated that the parent company requires approximately $250,000 per month to run its current level of operations. The engineering company was described as essentially self-sufficient and operating in a profitable mode, excluding R&D performed for BioLargo.
- Third-Party Capital FundingApproximately 86% of new capital raised on a cash basis came from outside the parent company. BioLargo brought in approximately $650,000 over about four months, while Clyra raised third-party capital to cover its large launch-related costs.
- Low Dilution in the First Half of Fiscal 2026Management noted that dilution was approximately 2.5% in the first half of 2026.
- Clyra Medical Distribution ExpansionClyra has three active distributors: Advanced Solutions, Al-Hikma, and Spartan Medical. Management said these channels may encompass more than 70% of the market, and the relationships were established in approximately seven months.
- Advanced Solutions Commercial ProgressAdvanced Solutions placed its first order and has stock and inventory. Its sales organization was described as approximately 350 to 400 people, and it is working with physicians, wound-care clinics, clinical personnel, and major health systems to establish adoption and distribution.
- International and Government Clyra ChannelsAl-Hikma is progressing through regulatory filings for sales in the Middle East, described as between one and 17 countries. Spartan Medical has begun work in the military, VA, and GSA channels, with approximately six or seven ViaCLYR SKUs included in its catalog.
- National Clyra Distribution Relationship AdvancingManagement said a fourth large national distribution relationship is advancing toward launch. The partner has built-in sales, distribution, pricing, and approvals for use, although some major systems will still require volume-pricing negotiations. Management described a potential setup period of approximately three to six months after the product and paperwork are finalized and referenced a 2027 start target.
- Clyra Product and Valuation MilestonesViaCLYR was described as an FDA-cleared product leveraging Clyrasept as an antimicrobial platform that can support dozens of product designs. Clyra has approximately 14 full-time employees, is raising additional capital, and was described as operating at an approximately $100 million valuation. BioLargo stated that it owns approximately 48% of Clyra, implying approximately $40 million of value based on that valuation.
- PFAS Commercial Reference Site and TrialsThe PFAS business has approximately 20 trials and its first commercial installation with a reference site. Management also cited approximately $1.7 million in total revenue from all water-related activities since inception.
- PFAS Technology and Aquatech AllianceBioLargo formed an alliance with Aquatech, which operates in 32 countries and was described as generating approximately $2 billion annually. The arrangement supports bidding as either a prime contractor or subcontractor by leveraging both companies’ resources.
- PFAS Application Breadth and Operating-Cost ProposalManagement stated that the PFAS technology has demonstrated efficacy across drinking water, wastewater, leachate, biosolids, and ultra-short-chain molecules. BioLargo proposed an approximately 80% reduction in operating expense compared with certain existing systems, and management said projects being scoped or bid range from $5 million to $10 million, with some ranging from $20 million to more than $40 million.
- Cellinity Battery Technology DevelopmentCellinity has more than 15 years of R&D and is being positioned around selling factories rather than batteries. Management cited evidence of 10 years with no degradation and an additional 10-year cycle with only 4% degradation under extreme testing conditions, compared with a market it characterized as having approximately a seven-year life and up to 15% degradation.
- Cellinity Factory Financing ModelManagement stated that a Cellinity factory would require approximately $170 million per facility and that the company’s broader capital expenditure requirement could be approximately $250 million. BioLargo intends to provide technology, engineering, procurement, design, and build services while obtaining minority equity, royalties, and revenue. A Puerto Rico project was described as potentially having more than 80% of project financing covered by incentives, while incentives of as much as 50% of capital expenditure were also cited.
- Tu Nipi Water Solutions VentureBioLargo announced a new Tu Nipi Water Solutions venture focused on water technology and business development in the Canadian oil sands region. Management cited oil sands process-affected water volumes of approximately 1.4 billion to 1.8 billion cubic meters and said the venture will address oil sands water as well as industrial wastewater, PFAS water, odor control, and engineering services.
- Minerals Facility Contract ProgressBioLargo is progressing a previously announced $1.1 million minerals facility contract toward Phase 2. Management described Phase 2 as a potential design-build engagement of approximately $10 million, followed by a potential commercial-scale design-build contract of approximately $40 million if the pilot is successful.
- BioLargo CPG Relaunch PlanBioLargo CPG is targeted to launch in October, initially using Amazon, Shopify, TikTok, social media, and other digital marketing channels. Management stated that BioLargo will own the brand and record gross sales, while using proven products, prior customer data, marketing experience, and a distributed team to support the relaunch.
- Potential CPG Revenue RampManagement said a conservative target based on approximately half of Pooph’s prior performance could produce more than $15 million over the first year to 1.5 years, although the ramp rate is uncertain and revenue would not occur all at once. Pooph was said to have generated approximately $125 million in gross sales over its lifecycle and approximately $60 million in peak 2025 run-rate sales.
- Portfolio Scale and Strategic OptionalityBioLargo described a portfolio of seven companies, with assets progressing through incubation, proof of claim, commercialization, regulatory clearance, partnership, manufacturing scale-up, and potential exits. Management cited joint ventures, licensing, asset sales, and IPOs as potential value-realization structures.
- Management Alignment and Potential UplistingManagement stated that executives, including Dennis Calvert and Ken Code, have made substantial investments in the company. Calvert and Code have also locked up their positions. Management said BioLargo intends to pursue an uplisting when revenues are predictable and the company can honor its investors.
BLGO Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 18, 2026 | 2026 (Q3) | -0.01- | -0.02 | ― | ― |
| Aug 17, 2026 | 2026 (Q2) | -0.01-0.01 | 0 | -150.00% (-0.01) | |
| May 20, 2026 | 2026 (Q1) | -0.01-0.01 | 0 | -75.00% (-0.00) | |
| Mar 05, 2026 | 2025 (Q4) | -0.01-0.01 | -0.01 | -100.00% (-0.01) | |
| Nov 17, 2025 | 2025 (Q3) | 0.00-0.02 | 0 | -900.00% (-0.02) | |
| Aug 14, 2025 | 2025 (Q2) | -0.01-0.00 | 0 | -300.00% (-0.00) | |
| May 15, 2025 | 2025 (Q1) | ―- | 0 | ― | |
| Mar 31, 2025 | 2024 (Q4) | 0.00-0.01 | 0 | ― | |
| Nov 14, 2024 | 2024 (Q3) | 0.00-0.00 | -0.01 | 80.00% (+0.01) | |
| Aug 14, 2024 | 2024 (Q2) | 0.00-0.00 | -0.01 | 90.00% (+0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

